Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
TLK286.2011
NCT00052065
February 2003
March 2006
Name | Location |
---|---|
M.D. Anderson Cancer Center | Houston, Texas 77030 |